Redefining precision medicine
ARTICLE
Pathway Bio is building a functional precision medicine platform to predict which therapies will be most effective for individual patients. We spoke to its CEO and co-founder Bobby Kaura about his experiences of launching the start-up and the KQ Labs entrepreneurial programme.
Evaluation of tumor response
PUBLICATION
Only 20 percent of renal and bladder cancer patients will show a signicant response to immune checkpoint inhibitor (ICI) therapy, and no test currently available accurately predicts ICI response.
Comprehensive Genomic Analysis
PUBLICATION
To select optimal therapies based on the detection of actionable genomic alterations in tumor samples is a major challenge in precision medicine.
